Navigation Links
Synosia Therapeutics Appoints Chief Financial Officer to New Company Headquarters in Switzerland
Date:2/4/2008

BASEL, Switzerland, February 4 /PRNewswire/ -- Synosia Therapeutics today announced the appointment of Philippe Lutz MA Finance, as the company's first chief financial officer, effective immediately. He will be based at Synosia's new headquarters in Basel, Switzerland.

Lutz joins Synosia from Credit Suisse Investment Banking where he most recently served as a vice president of the global markets solutions group. In a nine-year career at Credit Suisse, he contributed to a broad range of capital market transactions and successfully completed the chartered financial analyst exams (CFA). Lutz is a Swiss national and earned his masters in business administration from the University of St. Gallen.

"Since Synosia started operations just over two years ago, we've established partnerships with Roche, Novartis and Syngenta, designed and completed our first clinical trial, prepared to start four phase II trials later this year, and built strong teams in both San Francisco and Basel," said the company's Chief Executive Officer and President Ian Massey.

"The establishment of our corporate headquarters in Switzerland and the appointment of Philippe Lutz is a further step in our progression to a mature development organization; it also underscores the importance of Switzerland as a centre of excellence for the management, clinical development and extension of our portfolio of compounds," Dr Massey continued.

"I knew that Synosia was the company I wanted to join once I met the management team and saw the extraordinary progress the company has made," said Lutz. "I was also pleased to learn of the new headquarters in Switzerland. The strength of Switzerland's pharmaceutical sector should help sustain Synosia's ambitious development programme."

About Synosia Therapeutics

Synosia Therapeutics develops and intends to commercialize innovative and clinically differentiated products for unmet medical needs in psychiatry and neurology. The privately-owned company is developing six clinical-stage compounds acquired through key partnerships with Novartis, Roche and Syngenta. Synosia's pipeline includes two marketed drugs that will be tested in new indications, extending their reach into new neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's Disease. Synosia's corporate headquarters is in Basel, Switzerland.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Synosia Therapeutics and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Synosia Therapeutics to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Synosia Therapeutics is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Contact:

Synosia Therapeutics

In Europe:

Julie Walters at Tudor Reilly

Tel: +44(0)20-7016-7714

Mobile +44(0)775-3626967

julie.walters@tudor-reilly.com

In US:

Michele Parisi at Tudor Reilly

Tel: +1-925-864-5028

michele.parisi@tudor-reilly.com


'/>"/>
SOURCE Synosia Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders
2. Synosia Therapeutics Announces Appointment of Chief Business Officer
3. Taligen Therapeutics Secures Series B Financing
4. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
5. CV Therapeutics to Host Investor Science Day on Thursday, February 7, 2008
6. Sonexa Therapeutics, Inc., Raises $30 Million in Series A Financing to Focus on Alzheimers Treatments
7. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
8. CV Therapeutics to Announce 2007 Fourth Quarter and Year End Financial Results on Tuesday, February 26, 2008
9. Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc.
10. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
11. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... EDISON, N.J. , Feb. 4, 2016 ... company focused on the development and commercialization of targeted ... BIO CEO & Investor Conference 2016, to be held ... and Source Capital Group,s 2016 Disruptive Growth & Healthcare ... on February 10-11, 2016. James Sapirstein ...
(Date:2/4/2016)... , February 4, 2016 ... Laboratories (ABL), Inc. --> Strasbourg, France ... --> PharmaVentures is pleased to announce that it ... its biopharmaceutical manufacturing unit in Strasbourg, France ... --> --> Transgene (Euronext: ...
(Date:2/3/2016)... -- With the growing need for better therapeutics, and ... such as monoclonal antibodies, recombinant protein therapeutics and ... are in high demand. Conventionally expression systems were ... of these therapeutics. However, due to issues with ... approaches and novel expression systems are currently being ...
(Date:2/3/2016)... ... February 03, 2016 , ... ... a new office dedicated to the North American healthcare market. , Aerocom Healthcare, ... healthcare facilities. The company will provide new pneumatic tube systems or expand ...
Breaking Biology Technology:
(Date:1/20/2016)... Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... solutions, today announced sampling of S1423, its newest ... and small screen applications including smartwatches, fitness trackers, ... round and rectangular shapes, as well as thick ... with moisture on screen, while wearing gloves, and ...
(Date:1/13/2016)... New York , January 13, 2016 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2023. According to the ... in 2014 and is anticipated to reach US$1,625.8 mn ... 2015 to 2023. In terms of volume, the biometric ...
(Date:1/11/2016)... , Jan. 11, 2016  higi, the leading ... 10,000 retail locations, web and mobile, today announced ... million from existing investors. --> ... devoted to further innovate higi,s health platform – ... web portal – including expanding services and programs ...
Breaking Biology News(10 mins):